Furiex Pharmaceuticals, Inc. Receives FDA Fast Track Designation of MuDelta for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced that its novel diarrhea-predominant irritable bowel syndrome treatment called MuDelta, now in Phase II clinical trials, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).